Media Articles Related to Mozobil (Plerixafor Subcutaneous)
ESMO Guideline for Mantle Cell Lymphoma
Source: Medscape Hematology-Oncology Headlines [2014.09.25]
ESMO recently published its guideline for mantle cell lymphoma. Author Martin Dreyling highlights some of the key, evidence-based recommendations.
Canine lymphoma: new hope for beloved family pets
Source: Cancer / Oncology News From Medical News Today [2014.09.23]
Nearly one out of four dogs will develop cancer in their lifetime and 20 per cent of those will be lymphoma cases.
EU Commission grants marketing authorisation for Gilead's Zydelig® for the treatment of chronic lymphocytic leukaemia and follicular lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2014.09.22]
Gilead Sciences, Inc. has announced that the European Commission has granted marketing authorisation for Zydelig (idelalisib), 150 mg tablet, a first-in-class oral treatment for two incurable blood...
Researchers shed light on how breast implants may cause rare lymphoma
Source: Cosmetic Medicine / Plastic Surgery News From Medical News Today [2014.09.20]
Although uncommon, researchers have found that some women who have breast implants develop a rare form of non-Hodgkin lymphoma. A new study provides clues as to why this is.
PET-CT predicts lymphoma survival better than conventional imaging
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2014.09.18]
Positron emission tomography/computed tomography (PET-CT) is more accurate than conventional CT scanning in measuring response to treatment and predicting survival in patients with follicular...
Published Studies Related to Mozobil (Plerixafor Subcutaneous)
Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. [2009.12]
In a phase 3 multicenter, randomized, double-blinded, placebo-controlled study of 298 patients with non-Hodgkin lymphoma (NHL), granulocyte colony-stimulating factor (G-CSF) plus plerixafor increased the proportion of patients who mobilized >or=5 x 10(6) CD34(+) hematopoietic stem cells (HSCs)/kg compared with placebo plus G-CSF (P < .001).
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. [2009.10.01]
PURPOSE: This study evaluates the safety and efficacy of plerixafor (AMD3100), a CXCR4 antagonist, in mobilizing hematopoietic stem cells for autologous stem-cell transplantation in non-Hodgkin's lymphoma (NHL) patients... CONCLUSION: Plerixafor and G-CSF were well tolerated and resulted in a significantly higher proportion of patients with non-Hodgkin's lymphoma achieving the optimal CD34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. [2009.06.04]
This phase 3, multicenter, randomized (1:1), double-blind, placebo-controlled study evaluated the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G-CSF) in mobilizing hematopoietic stem cells in patients with multiple myeloma... Plerixafor and G-CSF were well tolerated, and significantly more patients collected the optimal CD34(+) cell/kg target for transplantation earlier compared with G-CSF alone.
Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. [2011.08.20]
Plerixafor (Mozobil(R)) is a CXCR4 chemokine receptor antagonist that is indicated for use in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize stem cells to the peripheral blood for collection and subsequent autologous stem-cell transplantation in patients who have non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) [US] and in patients who have lymphoma or MM and are poor mobilizers (EU)...
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. [2011.07]
The introduction of plerixafor has enabled successful collection of stem cells in the majority of patients with lymphoma or myeloma in whom previous attempts at mobilization have failed. However, a proportion of patients have been shown to be resistant to this mobilization regimen... Patients who are characterized by the above negative features could benefit potentially from further improvement in the mobilization strategy.
Clinical Trials Related to Mozobil (Plerixafor Subcutaneous)
Trial of an Augmented Mobilization Strategy With Plerixafor (MozobilÂ®) in a Population at Risk for Poor Stem Cell Mobilization [Recruiting]
Poor mobilization of hematopoietic progenitors needed to support autologous transplantation
is a serious clinical problem. We are investigating the role of plerixafor administered in
an at risk population to augment successful stem cell collection.
To determine if plerixafor when administered on the day prior to planned autologous
collection on first mobilization attempt in those with a peripheral blood CD34 â‰¤ 10X106/L
- increase the number of patients successfully collected in one day
- increase the number of patients successfully mobilized on first collection attempt
- is cost neutral within a Canadian setting
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant [Recruiting]
Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte
colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both
healthy volunteers and cancer patients. Furthermore, in cancer patients, cells collected
via apheresis using Plerixafor and G-CSF have been successfully transplanted. In December
2008, Plerixafor received approval from the Food and Drug administration for use in
combination with G-CSF to aid in mobilization of progenitor cells for apheresis. The
proposed study is not designed to support approval of a new indication or change in the
advertising for Plerixafor. The route of administration and dosage level are identical to
that which is listed on the package insert. Although Plerixafor is not approved for
patients with Hodgkins Lymphoma, there is no known or theoretic increased risk of the use of
this drug in this patient population.
The study hypothesis for this study is that patients with a circulating CD34+ count < 20
cells/ul after 5 days of mobilization with G-CSF alone will achieve > or equal to 2 X
10(6)CD34+ cells/kg within 3 days of apheresis after receiving Plerixafor with G-CSF.
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 kg [Not yet recruiting]
The purpose of this study is to compare the responses to 2 different doses of a drug called
plerixafor in subjects with Non-Hodgkins Lymphoma (NHL) who will receive an autologous stem
Time Alteration in Timing of Plerixafor Administration [Recruiting]
Typically, the collection of blood cells for autologous stem cell transplant is done after
the drugs granulocyte colony-stimulating factor (G-CSF) and plerixafor have been given to
activate the bone marrow stem cells to produce a certain type of blood cell, called CD34+
cells. Currently, plerixafor is given in the evening, about 11 hours before apheresis
(removal of blood) begins the following morning. The purpose of this study is to test
whether plerixafor can instead be given 17 hours before apheresis. This timing would be more
convenient since plerixafor would be given during normal clinic hours, and so patients would
be within a clinic environment if any side effects develop.
The study will look for the activation of CD34+ cells in patients who receive plerixafor 17
hours before apheresis. We will follow the number of patients that achieve the target
numbers of CD34+ cells, and the total number of CD34+ cells collected. These will be
compared to the numbers in previous studies giving plerixafor 11 hours before apheresis.
We will also assess the safety of giving plerixafor 17 hours before apheresis.
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma [Recruiting]
Plerixafor in combination with bevacizumab is a drug combination that may stop cancer cells
from growing abnormally. Bevacizumab, also known as Avastin, is FDA approved for use in
patients with recurrent glioblastoma and has been studied extensively in other types of
solid tumors. Plerixafor, also known as Mozobil, is FDA approved for use in patients with
non-Hodgkin's lymphoma and multiple myeloma and has been used in treatment for other
cancers. Information from experiments in laboratories suggests that the combination of
plerixafor and bevacizumab may help prevent the growth of gliomas.
Part 1: The investigators are looking for the highest dose of plerixafor that can be given
safely with bevacizumab (with a 21 days on/7 days off regimen of plerixafor). The
investigators will also do blood tests to find out how the body uses and breaks down the
Part 2: The investigators are looking to see if plerixafor can get past the blood-brain
barrier and into brain tumors. The investigators will also do blood tests to find out how
the body uses and breaks down the drug combination.
Part 3: The investigators are looking for for more information re: safety and tolerability
of plerixafor in combination with bevacizumab (with a 28 days on/0 days off regimen of
plerixafor). The investigators will also do blood tests to find out how the body uses and
breaks down the drug combination.
Reports of Suspected Mozobil (Plerixafor Subcutaneous) Side Effects
Febrile Neutropenia (30),
Respiratory Failure (15),
Pleural Effusion (14),
Interstitial Lung Disease (10),
Therapeutic Response Decreased (10), more >>